Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2024 02:00 ET | Source: Glycotope

Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting

Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a...
November 03, 2023 03:58 ET | Source: Glycotope

Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting

Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a...
December 13, 2022 02:00 ET | Source: Glycotope

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer San...
November 08, 2022 02:00 ET | Source: Glycotope

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 08 November, 2022 –...
March 24, 2022 03:00 ET | Source: Glycotope

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform Expansion of senior team to focus on drug discovery and developmentPlatform combines glycobiology...
November 15, 2021 03:00 ET | Source: Glycotope

Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting

Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting Glycotope Poster Presentation at the 2021 Society...
September 21, 2020 04:00 ET | Source: Glycotope

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 -...
July 30, 2018 03:00 ET | Source: Glycotope

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited...